Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.97USD
19 Jan 2018
Change (% chg)

$-0.01 (-0.25%)
Prev Close
$3.98
Open
$4.00
Day's High
$4.02
Day's Low
$3.94
Volume
230,072
Avg. Vol
300,263
52-wk High
$4.47
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Amarin Corp Plc ::AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK.AMARIN CORPORATION PLC SEES ‍UNAUDITED FULL-YEAR 2017 NET PRODUCT REVENUE ESTIMATED BETWEEN $177 AND $180 MILLION​.AMARIN - ‍WITHOUT ADJUSTMENT FOR IMPACT OF REDUCE-IT RESULTS, CO ESTIMATES 2018 NET PRODUCT REVENUE FROM VASCEPA WILL GROW TO ABOUT $230 MILLION​.AMARIN - ‍ESTIMATES IN EACH QUARTER OF 2018 NET PRODUCT REVENUE SHOULD GROW APPROXIMATELY 30% OR MORE AS COMPARED TO SAME QUARTER IN 2017​.AMARIN CORPORATION PLC - ‍ESTIMATES THAT ITS NET PRODUCT REVENUE IN Q1 2018 WILL BE BETWEEN $45 AND $48 MILLION​.AMARIN CORPORATION PLC - ‍ANTICIPATES THAT Q2 2018 RESULTS WILL REBOUND WITH NET PRODUCT REVENUE ANTICIPATED IN Q2 2018 OF $55 MILLION OR MORE​.  Full Article

Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018.AMARIN CORPORATION PLC - CONFIRMED IT IS ON TRACK TO REPORT TOP-LINE RESULTS FROM REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY BEFORE END OF Q3 2018.AMARIN - ‍MAINTAINS GUIDANCE THAT ONSET OF TARGETED 1,612TH PRIMARY MACE IN STUDY IS PROJECTED TO OCCUR BEFORE END OF Q1 2018​.  Full Article

Amarin reports Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Amarin :Amarin reports third quarter 2017 financial results and provides update on operations.Q3 loss per share $0.04.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - Qtrly net product revenue $47.1 million versus $32.4 million​.  Full Article

Amarin names Mark Salyer chief commercial officer
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Amarin Corporation Plc :Amarin appoints Mark W. Salyer to new position of chief commercial officer.Amarin remains on track to reach record product revenues of $165 to $175 million in 2017​.Most recently, Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC​.  Full Article

Amarin Corp prices public offering at $2.85 per ADS
Thursday, 11 Aug 2016 

Amarin Corporation Plc : Amarin prices public offering of american depositary shares . Pricing of underwritten public offering of 21.1 million American depositary shares at a price to public of $2.85 per ADS .Sees using net proceeds from offering to advance its reduce-it cardiovascular outcomes trial.  Full Article

Amarin Q2 loss per share $0.07
Thursday, 4 Aug 2016 

Amarin Corporation Plc : Q2 loss per share $0.07 . Amarin reports second quarter 2016 financial results and provides update on operations . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.13, revenue view $30.0 million -- Thomson Reuters I/B/E/S . Qtrly net total revenue $33.1 million versus $17.7 million .Q2 adjusted non-gaap loss per share $0.09 excluding items.  Full Article

Amarin says FDA to amend SPA agreement for cardiovascular outcomes study
Thursday, 4 Aug 2016 

Amarin Corporation Plc : Amarin and FDA reaffirm concurrence on REDUCE-IT through special protocol assessment agreement amendment . Continues to expect that DMC's 60%, 80% interim analyses will each result in a recommendation to continue reduce-it study as planned . Amendment does not change primary endpoint or overall size of reduce-it study or company's prior guidance on timing . Final efficacy analysis anticipated in 2018 .Secondary and tertiary endpoints of reduce-it study expanded.  Full Article

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage: